Baxter International Inc. with ticker code (BAX) now have 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The range between the high target price and low target price is between 58 and 44 suggesting an average Analsyt target price of $50.29. Given that the stocks previous close was at $41.65 and the analysts are correct then we can expect a percentage increase in value of 20.7%. The day 50 moving average is $44.72 and the 200 moving average now moves to $45.04. The market capitalization for the company is 21.44B. The stock price for the company is currently is currently 42.33 USD
The potential market cap would be $25,882,898,812 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 30.03 and a 3.7% return on assets.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s segments include Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia-Pacific), and Hillrom. The Americas, EMEA and APAC segments provide a portfolio of essential healthcare products, including acute and chronic dialysis therapies; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals, and surgical hemostat and sealant products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
